CLASSICAL HODGKIN LYMPHOMA

This study tests whether combining the drug pembrolizumab with a precise form of radiation can cure people with early-stage Hodgkin lymphoma that has returned or not responded to initial treatment. About 22 participants will receive this combination, with the goal of avoiding the…

This study tests whether combining two drugs, itacitinib and everolimus, can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatments. The trial is open to adults with measurable disease and aims to see how well the combination works in s…

This phase 2 study is testing a risk-adapted approach for children and young adults with classical Hodgkin lymphoma. Depending on their risk level, patients receive different combinations of chemotherapy drugs, with the goal of improving response while reducing side effects. The …

This phase 2 trial tests whether combining two drugs—nivolumab and axatilimab—can help people with classical Hodgkin lymphoma that has come back or not responded to prior treatments. The study includes 9 adults who have already tried at least one other therapy. Researchers will m…

This study tests a treatment plan that adjusts chemotherapy based on a patient's fitness level for adults aged 60 and older with untreated classical Hodgkin lymphoma. All participants receive the immunotherapy drug pembrolizumab plus another targeted drug, then a PET scan and fit…

This phase 2 trial tests whether replacing a standard chemo drug with Adcetris (brentuximab vedotin) can improve early tumor shrinkage in children with high-risk Hodgkin lymphoma. About 77 participants will receive two cycles of the new combo, followed by more chemo and possibly …

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (ABVD) can improve cure rates for people with high-risk Hodgkin lymphoma. About 82 participants with untreated stage III or IV disease are enrolled. The Phase I part checks safety and side e…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help children and young adults (ages 3-25) with newly diagnosed classical Hodgkin lymphoma who did not respond well to initial chemo. About 340 participants will receive pemb…

This study tests whether combining ibrutinib and nivolumab can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatment. About 18 adults will receive both drugs to see if the cancer shrinks or disappears. The goal is to improve disease con…

This phase 2 trial tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy (AVD) can improve outcomes for people with advanced classical Hodgkin lymphoma who have not yet been treated. About 60 adults aged 18 to 75 will receive the combination for up to …

This study is testing whether a blood test that looks for tumor DNA (called ctDNA) can predict if lymphoma will come back after first treatment. Researchers will compare this 'liquid biopsy' to standard PET scans in 108 adults with B-cell or Hodgkin lymphoma. The goal is to see i…